The companies commit to bring cutting-edge
liquid biopsy testing to 20 institutions globally over the next 12
months
BOSTON and ROLLE, Switzerland, Sept. 10,
2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH),
a cloud-native healthcare technology company and a global leader in
data-driven medicine, today announced a new milestone in the global
introduction of the liquid biopsy test MSK-ACCESS® powered with
SOPHiA DDM™, first announced in October
2023. Under a definitive partnership agreement with
AstraZeneca (LSE/STO/Nasdaq: AZN), SOPHiA GENETICS will accelerate
the deployment of MSK-ACCESS® powered with SOPHiA DDM™ to 20
locations worldwide over the next 12 months.
Liquid biopsy testing offers a complementary alternative to
solid tumor testing, which is not always feasible due to
insufficient tissue, low quality tissue, or the invasiveness of the
procedure. The testing works by isolating cell-free DNA (cfDNA)
from blood plasma to uncover circulating tumor DNA (ctDNA).
Isolating these DNA samples from a simple blood draw is less
invasive than a traditional biopsy, helping to simplify patient
monitoring and more quickly guide clinical decision-making.
MSK-ACCESS® powered with SOPHiA DDM™ is a
decentralized version of the highly validated liquid
biopsy test developed by Memorial Sloan Kettering Cancer Center
(MSK), a top cancer treatment and research institution. The
solution combines the sophisticated analytics, state-of-the-art
algorithms, and decentralized, cloud-based offerings
of the SOPHiA DDM™ Platform, with the scientific and clinical
expertise of MSK in cancer genomics to provide a best-in-class
liquid biopsy solution.
By increasing availability of MSK-ACCESS® powered with SOPHiA
DDM™, SOPHiA GENETICS and AstraZeneca aim to understand how liquid
biopsy testing can complement solid tissue testing, and in some
cases, provide greater benefit for labs and patients. This
understanding will help support the case for broad global
implementation. Additionally, through a dedicated real-world
evidence study, researchers will be able to evaluate the
operational benefits of liquid biopsy testing, including the speed
of results and the ability of users to consistently achieve
high-quality data in a variety of laboratory settings.
"Our collaboration with AstraZeneca has the potential to
dramatically accelerate global access to liquid biopsy testing,
especially in underserved populations, which in turn could
contribute to reshaping diagnostics, treatment, and monitoring of
cancer cases throughout the world. Their support is instrumental to
making this improved access a reality," said Philippe Menu, M.D.,
Ph.D, Chief Medical and Chief Product Officer, SOPHiA GENETICS. "Additionally, the breadth and
depth of real-world data that we will generate through the
implementation of this decentralized liquid biopsy
testing platform on a global scale will be unprecedented, providing
novel avenues to accelerating cancer research."
Since launching MSK-ACCESS powered with SOPHiA DDM™ in
April 2024, a first wave of 14
leading healthcare institutions worldwide have signed on to
piloting and adopting the application. These institutions include
renowned cancer centers and reference laboratories such as:
BioReference® and Tennessee Oncology in the U.S.; Oncohelix in
Canada; Dasa in Brazil; Universitätsklinikum Heidelberg in
Germany; Stavanger University
Hospital in Norway; IUCT Oncopole
in France; Synnovis and South West
Genomic Laboratory Hub, operating out of North Bristol NHS Trust in
the U.K.; Sofiva Genomics in Taiwan; Syndicate Bio in Nigeria; A.O.U. Senese in Italy; and Karkinos Healthcare and Strand Life
Sciences in India.
The partnership with AstraZeneca will further catalyze the
adoption of MSK-ACCESS® powered with SOPHiA DDM™.
As more hospitals and labs go into routine, SOPHiA GENETICS and
AstraZeneca, in collaboration with leading cancer institutes within
the SOPHiA GENETICS community, will generate a vast set of
real-world data from patients around the world with a variety of
cancers. This data set has the potential to generate unique
insights towards advancing cancer research and drug
development.
"We are deeply committed to bringing liquid biopsy expertise to
labs and institutions throughout the globe at an expedited pace,
and are confident this rollout will further support access to
testing and aid in providing data-driven treatment options to
patients around the world," said Kristina Rodnikova, Head of Global
Oncology Diagnostics, AstraZeneca.
The deployment of MSK-ACCESS® powered with SOPHiA DDM™ was
announced in October 2023 as part of
a collaboration between SOPHiA GENETICS, AstraZeneca and MSK.
Together, the three companies are working to combat global health
inequities and advance cancer research.
For more information on SOPHiA GENETICS,
visit SOPHiAGENETICS.COM, or connect
on LinkedIn.
About SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH) is a cloud-native healthcare
technology company on a mission to expand access to
data-driven medicine by using AI to deliver world-class care to
patients with cancer and rare disorders across the globe.
It is the creator of the SOPHiA DDM™ Platform, which analyzes
complex genomic and multimodal data and
generates real-time, actionable insights for a broad
global network of hospital, laboratory, and biopharma
institutions. For more information,
visit SOPHiAGENETICS.COM and connect with us
on LinkedIn.
SOPHiA GENETICS products are for Research Use Only and not
for use in diagnostic procedures unless specified otherwise. The
information in this press release is about products that may or may
not be available in different countries and, if applicable, may or
may not have received approval or market clearance by a
governmental regulatory body for different indications for use.
Please contact support@sophiagenetics.com to obtain the appropriate
product information for your country of residence.
Memorial Sloan Kettering (MSK)
has institutional financial interests related to SOPHiA
GENETICS.
SOPHiA GENETICS Forward-Looking
Statements:
This press release contains statements that constitute
forward-looking statements. All statements other than statements of
historical facts contained in this press release, including
statements regarding our future results of operations and financial
position, business strategy, products, and technology, as well as
plans and objectives of management for future operations, are
forward-looking statements. Forward-looking statements are based on
our management's beliefs and assumptions and on information
currently available to our management. Such statements are subject
to risks and uncertainties, and actual results may differ
materially from those expressed or implied in the forward-looking
statements due to various factors, including those described in our
filings with the U.S. Securities and Exchange Commission. No
assurance can be given that such future results will be achieved.
Such forward-looking statements contained in this press release
speak only as of the date hereof. We expressly disclaim any
obligation or undertaking to update these forward-looking
statements contained in this press release to reflect any change in
our expectations or any change in events, conditions, or
circumstances on which such statements are based, unless required
to do so by applicable law. No representations or warranties
(expressed or implied) are made about the accuracy of any such
forward-looking statements.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/sophia-genetics-and-astrazeneca-collaborate-to-further-expand-global-access-to-liquid-biopsy-testing-302243805.html
SOURCE SOPHiA GENETICS